Last updated: May 30, 2022
Sponsor: Andreas Josefsson
Overall Status: Terminated
Phase
2
Condition
Covid-19
Treatment
N/AClinical Study ID
NCT04475601
COVIDENZA
Ages > 50 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Positive COVID-19 test
- Mild to severe symptoms of COVID-19
- Hospitalization
- WHO performance status 0-3
- Age above or equal to 50 years
- Can understand all the requirements of the study, provide informed consent, andprovide authorization of use and disclosure of personal health information.
- Estimated expected survival of 1 year (excluding symptoms due to COVID-19)
Exclusion
Exclusion Criteria:
- Severe allergy to Enzalutamide
- Pregnant or breast-feeding women
- Need of immediate mechanical ventilation
- Current medication includes enzalutamide treatment
- Stroke or Transitory Ischemic attack in medical history
- Treatment for HIV
- Treatment with tamoxifen
- Treatment with immunosuppressive agents
- Severe immunosuppressive disease
- Treatment with warfarin or NOAC (Non-vitamin K-antagonist anticoagulants)
- Previous seizure in medical history
- Other serious illness or medical condition
- Unstable cardiovascular disease
Study Design
Total Participants: 42
Study Start date:
July 15, 2020
Estimated Completion Date:
May 29, 2021
Connect with a study center
Anders Bjartell
Malmö, Skåne
SwedenSite Not Available
Ryhovs Hospital
Jönköping, Småland
SwedenSite Not Available
Sahlgrenska University Hospital
Gothenburg,
SwedenSite Not Available
Linköping University Hospital
Linköping,
SwedenSite Not Available
Sundsvall Region Hosptial
Sundsvall,
SwedenSite Not Available
Umeå Univerisity Hospital
Umeå,
SwedenSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.